HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praecis Pharmaceuticals Inc.

Division of GlaxoSmithKline PLC
www.praecis.com

Latest From Praecis Pharmaceuticals Inc.

Europe's New Spec Pharma Models

Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Europe North America

Genmab/GSK: An Impressive Display of Biotech's Increased Leverage

Cash-rich and product-poor pharmaceutical firms playing catch-up in large molecules have turned 2006 into a bumper year for dealmaking. Even so, Genmab AS's monster December deal with GSK for worldwide rights to the Phase III anti-CD20 antibody ofatumumab (HuMax-CD20), which includes a whopping $459 million in up-front cash and equity payments, seemed to catch analysts by surprise, beating even optimistic expectations
BioPharmaceutical Business Strategies

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
BioPharmaceutical

Millennium: Leaving Europe to Partners

When it comes to Europe, the biotech industry is increasingly saying "no." The latest refusenik: Millennium Pharmaceuticals Inc. That's because Schering-Plough Corp., beset by a host of management and competitive problems, had seen European sales of Millennium's eptifibatide (Integrilin) weaken and decline-and they had never been strong. Merck & Co. Inc.'s tirofiban (Aggrastat), a weak number three in the IIb/IIIa inhibitor US market, had nearly twice Integrilin's sales in Europe; Johnson & Johnson's abciximab (Reopro) had about ten times Integrilin's sales. Millennium re-acquired the European rights and then immediately sold them again, this time to GlaxoSmithKline PLC
Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Pharmaceutical Peptides Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Kevin F McLaughlin, CEO
    Edward C English, VP, CFO
    Malcolm L Gefter, PhD, CSO
    Michael J Keavany, SVP, Sales & Mktg.
  • Contact Info
  • Praecis Pharmaceuticals Inc.
    Phone: (781) 795-4100
    830 Winter St.
    Waltham, MA 02451-1420
    USA
UsernamePublicRestriction

Register